1887

Abstract

The immunogenicity of variable regions of hepatitis C virus (HCV) proteins was studied by ELISA by using 543 synthetic peptides from 120 variable regions and 90 sera from HCV-infected patients. Some regions from certain genotypes were less immunogenic, or even non-immunogenic, compared with their equivalents in other genotypes. However, the mean recognition of all peptides from genotypes 1a, 1b and 3 by sera infected with genotypes 1a, 1b and 3, respectively, showed no significant differences, suggesting a similar overall immunogenicity of variable regions from these genotypes. Proteins NS4a, NS4b and NS5a were found to be the most immunogenic. Recognition of individual peptides by the sera of infected patients showed that the humoral response against HCV is patient-dependent. The work shows that 15-mer peptides may encompass several B-cell epitopes. These epitopes may lie in slightly different positions in different genotypes. Thirty-one percent of the 543 peptides were recognized by some of the 35 healthy donors. This may be a reflection of the large number of antigens to which they had been exposed, but it may also reflect a strategy of HCV to respond to immune pressure. After selection and modification, a set of 40 peptides was used to assess genotypes 1a, 1b, 1, 2 and 3 in the sera of HCV-infected patients, with sensitivities of 34.1, 48.5, 68.8, 58.3 and 48.9% and specificities of 100, 99.1, 97.1, 99.5 and 99%, respectively. The overall sensitivity and specificity for the assessment of genotypes 1, 2 and 3 were 64 and 98%, respectively.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-80-3-727
1999-03-01
2022-08-17
Loading full text...

Full text loading...

/deliver/fulltext/jgv/80/3/0800727a.html?itemId=/content/journal/jgv/10.1099/0022-1317-80-3-727&mimeType=html&fmt=ahah

References

  1. Agence du Médicaments, France 1996; Drug agency evaluation of RIBA serotyping versus Murex HCV serotyping 1−3. Report on Murex Assay.
    [Google Scholar]
  2. Alter H. J. 1989; Chronic consequences of non−A, non−B hepatitis. In Current Prospective in Hepatology pp 83–87 New York: Plenum;
    [Google Scholar]
  3. Atherton E., Logan J., Sheppard C. 1981; Peptide synthesis. Part 2. Procedures for solid phase synthesis using N-fluorenil metoxycarbonil amino acids on polyamide supports. Synthesis of substance P and of acyl carrier protein 65–74 decapeptide. Journal of the Chemical Society Perkin Transactions 1:538–546
    [Google Scholar]
  4. Bell H., Hellum K., Harthug S., Maeland A., Ritland S., Myrvang B., von der Lippe B., Raknerud N., Skaug K., Gutigard B. G., Skjaerven R., Prescott L. E., Simmonds P. 1997; Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct Group. Scandinavian Journal of Infectious Diseases 29:17–22
    [Google Scholar]
  5. Berasain C., Garcia-Granero M., Riezu-Boj J. I., Prieto J., Borras-Cuesta F. 1993; Detection of anti-hepatitis C virus antibodies by ELISA using synthetic peptides. Journal of Hepatology 18:80–84
    [Google Scholar]
  6. Borrás-Cuesta F., Fedon Y., Petit-Camurdan A. 1988; Enhancement of peptide immunogenicity by linear polymerization. European Journal of Immunology 18:199–202
    [Google Scholar]
  7. Borrás-Cuesta F., Golvano J., Sarobe P., Lasarte J. J., Prieto I., Szabo A., Guillaume J. L., Guillet J.-G. 1991; Insight s on the amino acid side-chain interactions of a synthetic T-cell determinant. Biologicals 19:187–190
    [Google Scholar]
  8. Brechot C. 1996; Hepatitis C virus: molecular biology and genetic variability. Digestive Diseases and Sciences 41: Suppl 126S–21S
    [Google Scholar]
  9. Bukh J., Purcell R. H., Miller R. H. 1993; At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. Proceedings of the National Academy of Sciences, USA 90:8234–8238
    [Google Scholar]
  10. Cerino A., Cividini A., Asti M., Lanza A., Silini E., Mondelli M. 1996; Comparative evaluation of two serologic typing methods for hepatitis C virus. Journal of Clinical Microbiology 34:714–716
    [Google Scholar]
  11. Choo Q. L., Weiner A. J., Overby L. R., Bradley D. W., Houghton M. 1989; Isolation of a cDNA clone derived from a blood borne non-A, non-B viral hepatitis genome. Science 244:359–362
    [Google Scholar]
  12. Choo Q. L., Richman K. H., Han J. H., Berger K., Lee C., Dong C., Gallegos C., Coit D., Medina-Selby R., Barr P. J., Weiner A. J., Bradley D. W., Kuo G., Houghton M. 1991; Genetic organization and diversity of the hepatitis C virus. Proceedings of the National Academy of Sciences, USA 88:2451–2455
    [Google Scholar]
  13. Darwish M. A., Raouf T. A., Rushdy P., Constantine N. T., Rao M. R., Edelman R. 1993; Risk factors associated with a high seroprevalence of hepatitis C virus infection in Egyptian blood donors. American Journal of Tropical Medicine and Hygiene 49:440–447
    [Google Scholar]
  14. Davidson F., Simmonds P., Ferguson J. C., Jarvis L. M., Dow B. C., Follett E. A. C., Seed C. R. G., Krusius T., Lin C., Medgyesi G. A., Kiyokawa H., Olim G., Duraisamy G., Cuypers T., Saeed A. A., Teo D., Conradie J., Kew M. C., Lin M., Nuchaprayoon C., Ndimbie O. K., Yap P. L. 1995; Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5« non-coding region. Journal of General Virology 76:1197–1204
    [Google Scholar]
  15. Davis G. L., Lau J. Y. N. 1997; Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 26:Suppl 1122S–127S
    [Google Scholar]
  16. Dhaliwal S. K., Prescott L. E., Dow B. C., Davidson F., Brown H., Yap P. L., Follett E. A., Simmonds P. 1996; Influence of viraemia and genotype upon serological reactivity in screening assays for antibody to hepatitis C virus. Journal of Medical Virology 48:184–190
    [Google Scholar]
  17. Dusheiko G., Schmilovitz-Weiss H., Brown D., McOmish F., Yap P. L., Sherlock S., McIntyre N., Simmonds P. 1994; Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 19:13–18
    [Google Scholar]
  18. Forns X., Maluenda M. D., Lopez-Labrador F. X., Ampurdanés S., Olmedo E., Costa J., Simmonds P., Sanchez-Tapias J. M., Jimenez De Anta M. T., Rodes J. 1996; Comparative study of three methods for genotyping hepatitis C virus strains in samples from Spanish patients. Journal of Clinical Microbiology 34:2516–2521
    [Google Scholar]
  19. Garson J. A., Ring C., Tuke P., Tedder R. S. 1990; Enhanced detection by PCR of hepatitis C virus RNA. Lancet ii:878–879
    [Google Scholar]
  20. Gavier B., Martínez-Gonzalez M. A., Riezu-Boj J. I., Lasarte J. J., Garcia N., Civeira M. P., Prieto J. 1997; Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology 113:1647–1653
    [Google Scholar]
  21. Gournay J., Marcellin P., Martinot-Peignoux M., Degott C., Gabriel F., Courtois F., Branger M., Wild A. M., Erlinger S., Benhamou J. P. 1995; Hepatitis C virus genotypes in French blood donors. Journal of Medical Virology 45:399–404
    [Google Scholar]
  22. Hino K., Sainokami S., Shimoda K., Lino S., Wang Y., Okamoto H., Miyakawa Y., Mayumi M. 1994; Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. Journal of Medical Virology 42:299–305
    [Google Scholar]
  23. Hopf V., Berg T., Ko nig V., Kuther S., Heuft H. G., Lobeck H. 1996; Treatment of chronic hepatitis C with interferon alpha: long-term follow up and prognosis relevance of HCV genotypes. Journal of Hepatology 24: Suppl 267–73
    [Google Scholar]
  24. Kato N., Hijikata M., Ootsuyama Y., Nakagawa M., Ohkoshi S., Sugimura T., Shimotohno K. 1990; Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proceedings of the National Academy of Sciences, USA 87:9524–9528
    [Google Scholar]
  25. Ko Y. C., Ho M. S., Chiang T. A., Chang S. J., Chang P. Y. 1992; Tattooing as a risk of hepatitis C virus infection. Journal of Medical Virology 38:288–291
    [Google Scholar]
  26. Kuo G., Choo Q., Alter H., Gitnick G., Redeker A., Purcell R., Miyamura T., Dienstag J. L., Alter M. J., Stevens C. E., Tegtmeier G., Bonino F., Colombo M., Lee W., Kuo C., Berger K., Shuster J., Overby L., Bradley D., Houghton M. 1989; An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244:362–364
    [Google Scholar]
  27. Larrea E., García N., Qian C., Civeira M. P., Prieto J. 1996; Tumor necrosis factor α gene expression and the response to interferon in chronic hepatitis C. Hepatology 23:210–217
    [Google Scholar]
  28. Lau J. Y. N., Mizokami M., Ohno T., Diamond D. A., Kniffen J., Davis G. L. 1993; Discrepancy between biochemical and virological responses to interferon-α in chronic hepatitis C. Lancet 342:1208–1209
    [Google Scholar]
  29. Lohr H. F., Elste C., Dienes H. P., Michel G., Braun H. B., Meyer zum Buschenfelde K. H., Gerken G. 1996; The quantitative humoral immune response to the hepatitis C virus is correlated with disease activity and response to interferon-alpha. Journal of Hepatology 25:292–300
    [Google Scholar]
  30. Machida A., Ohnuma H., Tsuda F., Munekata E., Tanaka T., Akahane Y., Okamoto H., Mishiro S. 1992; Two distinct subtypes of hepatitis C virus defined by antibodies directed to putative core protein. Hepatology 16:886–891
    [Google Scholar]
  31. Martinot-Peignoux M., Marcellin P., Pouteau M., Castelnau C., Boyer N., Poliquin M., Degott C., Descombes I., Le Breton V., Milotova V., Benhamou J. P., Erlinger S. 1995; Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon-alpha therapy in chronic hepatitis C. Hepatology 22:1050–1056
    [Google Scholar]
  32. Mellor J., Holmes E. C., Jarvis L. M., Yap P. L., Simmonds P. The International HCV Collaborative Study Group 1995; Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. Journal of General Virology 76:2493–2507
    [Google Scholar]
  33. Merrifield R. 1963; Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. Journal of the American Chemical Society 85:2149–2154
    [Google Scholar]
  34. Okamoto H., Sugiyama Y., Okada S., Kurai K., Akahane Y., Sugai Y., Tanaka T., Sato K., Tsuda F., Miyakawa Y., Mayumi M. 1992; Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. Journal of General Virology 73:673–679
    [Google Scholar]
  35. Pawlotsky J. M., Prescott L., Simmonds P., Pellet C., Laurent-Puig P., Labonne C., Darthuy F., Remire J., Duval J., Buffet C., Etienne J. P., Dhumeaux D., Dussaix E. 1997; Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. Journal of Clinical Microbiology 35:1734–1739
    [Google Scholar]
  36. Pereira B. J., Milford E. L., Kirkman R. L., Levey A. S. 1991; Transmission of hepatitis C virus by organ transplantation. New England Journal of Medicine 325:454–460
    [Google Scholar]
  37. Polish L. B., Tong M. J., Co R. L., Coleman P. J., Alter M. J. 1993; Risk factors for hepatitis C virus infection among health care personnel in a community hospital. American Journal of Infection Control 21:196–200
    [Google Scholar]
  38. Pozzato G., Kaneko S., Moretti M., Saveria L., Franzin F., Unoura M., Bercich L., Tiribelli C., Crovatto M., Santini G., Kobayashi K. 1994; Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease. Journal of Medical Virology 43:291–296
    [Google Scholar]
  39. Rall C. J., Dienstag J. L. 1995; Epidemiology of hepatitis C virus infection. Seminars in Gastrointestinal Disease 6:3–12
    [Google Scholar]
  40. Sakugawa H., Nakasone H., Kinjo F., Saito A., Keida Y., Kikuchi K., Oyadomari Y., Ishihara M., Nakasone K., Yogi S., Kinjo Y., Taira M. 1997; Clinical features of patients with chronic liver disease associated with hepatitis C virus genotype 1a/I in Okinawa, Japan. Journal of Gastroenterology and Hepatology 12:176–181
    [Google Scholar]
  41. Sarobe P., Lasarte J. J., Golvano J. J., Prieto I., Gullon A., Soto M. J., Labarga P., Prieto J., Borrás-Cuesta F. 1994; Induction of neutralizing antibodies against human immunodeficiency virus type 1 using synthetic peptide constructs containing an immunodominant T-helper cell determinant from vpr. Journal of Acquired Immune Deciency Syndromes 7:635–640
    [Google Scholar]
  42. Shakil A. O., Conry-Cantilena C., Alter H. J., Hayashi P., Kleiner D. E., Tedeschi V., Krawczynski K., Conjeevaram H. S., Sallie R., Di Bisceglie A. M. 1995; Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Annals of Internal Medicine 123:330–337
    [Google Scholar]
  43. Simmonds P. 1995; Variability of hepatitis C virus. Hepatology 21:570–583
    [Google Scholar]
  44. Simmonds P., Rose K. A., Graham S., Chan S. W., McOmish F., Dow B. C., Follett E. A., Yap P. L., Marsden H. 1993; Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3. Journal of Clinical Microbiology 31:1493–1503
    [Google Scholar]
  45. Simmonds P., Alberti A., Alter H. J., Bonino F., Bradley D. W., Brechot D., Brouwer J. T., Chan S. W., Chayama K., Chen D. S., Choo Q.-L., Colombo M., Cuypers H. T. M., Date T., Dusheiko G. M., Esteban J. I., Fay O., Hadziyannis S. J., Han J., Hatzakis A., Holmes D. C., Hotta H., Houghton M., Irvine B., Kohara M., Kolberg J. A., Kuo G., Lau J. Y. N., Lelie P. N., Maertens G., McOmish F., Miyamura T., Mizokami M., Nomoto A., Prince A. M., Reesink H. W., Rice C., Roggendorf M., Schalm S., Shikata T., Shimotohno K., Stuyver L., Trepo C., Weiner A., Yap P. L., Urdea M. S. 1994; A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 19:1321–1334
    [Google Scholar]
  46. Smith D. B., Pathirana S., Davidson F., Lawlor E., Power J., Yap P. L., Simmonds P. 1997; The origin of hepatitis C virus genotypes. Journal of General Virology 78:321–328
    [Google Scholar]
  47. Takada A., Tsutsumi M., Zhang S. C., Okanoue T., Matsushima T., Fujiyama S., Komatsu M. 1996; Relationship between hepatocellular carcinoma and subtypes of hepatitis C virus: a nationwide analysis. Journal of Gastroenterology and Hepatology 11:166–169
    [Google Scholar]
  48. Takamizawa A., Mori C., Fuke Y., Manabe S., Murakami S., Fujita J., Onishi E., Andoh T., Yoshida I., Okayama H. 1991; Structure and organization of the hepatitis C virus genome isolated from human carriers. Journal of Virology 65:1105–1113
    [Google Scholar]
  49. Tanaka T., Tsukiyama−Kohara K., Yamaguchi K., Yagi S., Tanaka S., Hasegawa A., Ohta Y., Hattori N., Kohara M. 1994; Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 19:1347–1353
    [Google Scholar]
  50. Tsubota A., Chayama K., Ikeda K., Yasuji A., Koida I., Saitoh S., Hashimoto M., Iwasaki S., Kobayashi M., Hiromitsu K. 1994; Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 19:1088–1094
    [Google Scholar]
  51. Tsukiyama-Kohara K., Kohara M., Yamaguchi K., Maki N., Toyoshima A., Miki K., Tanaka S., Hattori N., Nomoto A. 1991; A second group of hepatitis C viruses. Virus Genes 5:243–254
    [Google Scholar]
  52. Tsukiyama-Kohara K., Yamaguchi K., Maki N., Ohta Y., Miki K., Mizokami M., Ohba K., Tanaka S., Hattoti N., Nomoto A., Kohara M. 1993; Antigenicities of group I and II hepatitis C virus polypeptides – molecular basis of diagnosis. Virology 192:430–437
    [Google Scholar]
  53. Tsukuma H., Hiyama T., Tanaka S., Nakao M., Yabuuchi T., Kitamura T., Nakanishi K., Fujimoto I., Inoue A., Yamazaki H., Kawashima T. 1993; Risk factors for hepatocellular carcinoma among patients with chronic liver disease. New England Journal of Medicine 328:1797–1801
    [Google Scholar]
  54. van Doorn L. J., Kleter B., Pike I., Quint W. 1996; Analysis of hepatitis C virus isolates by serotyping and genotyping. Journal of Clinical Microbiology 34:1784–1787
    [Google Scholar]
  55. Viazov S., Zibert A., Ramakrishnan K., Widell A., Cavicchini A., Schreier E., Roggendorf M. 1994; Typing of hepatitis C virus isolates by DNA enzyme immunoassay. Journal of Virological Methods 48:81–91
    [Google Scholar]
  56. Vrielink H., Zaaijer H. L., Reesink H. W., Lelie P. N., van der Poel C. L. 1995; Comparison of two anti-hepatitis C virus enzyme-linked immunosorbent assays. Transfusion 35:601–604
    [Google Scholar]
  57. Yamada G., Takahashi M., Miyamoto R., Tsuji T., Yoshizawa H., Okamoto H. 1994; Prediction of interferon effect in chronic hepatitis C by both quantification and genotyping of HCV-RNA. Digestive Diseases and Sciences 39:441
    [Google Scholar]
  58. Yoshioka K., Kakumu S., Wakita T., Ishikawa T., Itoh Y., Takayanagi M., Higashi Y., Shibata M., Morishima T. 1992; Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 16:293–299
    [Google Scholar]
  59. Zein N. N., Rakela J., Poterucha J. J., Steers J. L., Wiesner R. H., Persing D. H. 1995a; Hepatitis C genotypes in liver transplant recipients: distribution and 1-year follow-up. Liver Transplantation and Surgery 1:354–357
    [Google Scholar]
  60. Zein N. N., Poterucha J. J., Wiesner R. H., Gross J. B., Gossard A. A., Wendt N. K., Mitchell P. S., Germer J. J., Persing D. H. 1995b; Hepatocellular carcinoma in patients infected with different hepatitis C genotypes. Gastroenterology 108: Suppl 1A1207
    [Google Scholar]
  61. Zein N. N., Rakela J., Krawitt E. L., Reddy K. R., Tominaga T., Persing D. H. 1996; Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Annals of Internal Medicine 125:634–639
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-80-3-727
Loading
/content/journal/jgv/10.1099/0022-1317-80-3-727
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error